Blood mononuclear cell proteome suggests integrin and ras signaling as critical pathways for antidepressant treatment response

Biological Psychiatry

Volumn 76, Issue 7, 2014, Pages e15-e17

  Martins De souza, Daniel ^a,b,c   Maccarrone, Giuseppina ^a   Ising, Marcus ^a   Kloiber, Stefan ^a   Lucae, Susanne ^a   Holsboer, Florian ^a   Turck, Christoph W ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 1; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; CAPNS1 PROTEIN; INTEGRIN; INTEGRIN LINKED KINASE; ITGB3 PROTEIN; LIMS1 PROTEIN; PROTEIN CDC42; PROTEOME; RAC2 PROTEIN; RAS PROTEIN; TTN PROTEIN; UNCLASSIFIED DRUG; ZYX PROTEIN;

CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HAMILTON DEPRESSION RATING SCALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; LETTER; LIQUID CHROMATOGRAPHY; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NEUROTRANSMISSION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; TREATMENT RESPONSE; WESTERN BLOTTING; ADULT; AGED; BLOOD; DEPRESSIVE DISORDER, MAJOR; FEMALE; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; YOUNG ADULT;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INTEGRINS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROTEOMICS; RAS PROTEINS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922680254     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2014.01.022     Document Type: Letter

References (30)

1. Fava GA (1999): Subclinical symptoms in mood disorders: Pathophysiological and therapeutic implications. Psychol Med 29:47-61.
2. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, Khawaja X, Rajarao SJ, Malberg JE, et al. (2007): Differentiating antidepressants of the future: Efficacy and safety. Pharmacol Ther 113:134-153.
3. Martins-de-Souza D (2013): Biomarkers for psychiatric disorders: Where are we standing? Dis Markers 35:1-2.
4. Labermaier C, Masana M, Mueller M (2013): Biomarkers predicting antidepressant treatment response: How can we advance the field? Dis Markers 35:23-31.
5. Oliveira BM, Schmitt A, Falkai P, Martins-de-Souza D (2013): Is clinical proteomics heading towards to bench to bedside? Transl Proteomics 1:3.
6. Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S, et al. (2009): Clinical characteristics and treatment outcome in a representative sample of depressed inpatients-findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 43:215-229.
7. Maccarrone G, Rewerts C, Lebar M, Turck CW, Martins-de-Souza D (2013): Proteome profiling of peripheral mononuclear cells from human blood. Proteomics 13:893-897.
8. Maccarrone G, Turck CW, Martins-de-Souza D (2010): Shotgun mass spectrometry workflow combining IEF and LC-MALDI-TOF/TOF. Protein J 29:99-102.
9. Martins-de-Souza D (2010): Is the word 'biomarker' being properly used by proteomics research in neuroscience? Eur Arch Psychiatry Clin Neurosci 260:561-562.
10. McGeachie AB, Cingolani LA, Goda Y (2011): Stabilising influence: Integrins in regulation of synaptic plasticity. Neurosci Res 70:24-29.
11. McGeachie AB, Skrzypiec AE, Cingolani LA, Letellier M, Pawlak R, Goda Y (2012): Beta3 integrin is dispensable for conditioned fear and hebbian forms of plasticity in the hippocampus. Eur J Neurosci 36: 2461-2469.
12. Carter MD, Shah CR, Muller CL, Crawley JN, Carneiro AM, Veenstra-VanderWeele J (2011): Absence of preference for social novelty and increased grooming in integrin beta3 knockout mice: Initial studies and future directions. Autism Res 4:57-67.
13. Cingolani LA, Thalhammer A, Yu LM, Catalano M, Ramos T, Colicos MA, et al. (2008): Activity-dependent regulation of synaptic AMPA receptor composition and abundance by beta3 integrins. Neuron 58:749-762.
14. Carneiro AM, Cook EH, Murphy DL, Blakely RD (2008): Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J Clin Invest 118:1544-1552.
15. Chain DG, Schwartz JH, Hegde AN (1999): Ubiquitin-mediated proteolysis in learning and memory. Mol Neurobiol 20:125-142.
16. Fukuo Y, Kishi T, Kushima I, Yoshimura R, Okochi T, Kitajima T, et al. (2011): Possible association between ubiquitin-specific peptidase 46 gene and major depressive disorders in the Japanese population. J Affect Disord 133:150-157.
17. Matthys A, Van Craenenbroeck K, Lintermans B, Haegeman G, Vanhoenacker P (2012): RhoBTB3 interacts with the 5-HT7a receptor and inhibits its proteasomal degradation. Cell Signal 24:1053-1063.
18. Mouri A, Sasaki A, Watanabe K, Sogawa C, Kitayama S, Mamiya T, et al. (2012): MAGE-D1 regulates expression of depression-like behavior through serotonin transporter ubiquitylation. J Neurosci 32:4562-4580.
19. Elias M, Brighouse A, Gabernet-Castello C, Field MC, Dacks JB (2012): Sculpting the endomembrane system in deep time: High resolution phylogenetics of Rab GTPases. J Cell Sci 125:2500-2508.
20. McCormick F (1995): Ras-related proteins in signal transduction and growth control. Mol Reprod Dev 42:500-506.
21. Golden SA, Christoffel DJ, Heshmati M, Hodes GE, Magida J, Davis K, et al. (2013): Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nat Med 19:337-344.
22. Lopez-Munoz F, Alamo C (2009): Monoaminergic neurotransmission: The history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 15:1563-1586.
23. Penn E, Tracy DK (2012): The drugs don't work? Antidepressants and the current and future pharmacological management of depression. Ther Adv Psychopharmacol 2:179-188.
24. Kumamaru E, Numakawa T, Adachi N, Kunugi H (2011): Glucocorticoid suppresses BDNF-stimulated MAPK/ERK pathway via inhibiting interaction of Shp2 with TrkB. FEBS Lett 585:3224-3228.
25. Kerman IA (2012): New insights into BDNF signaling: Relevance to major depression and antidepressant action. Am J Psychiatry 169: 1137-1140.
26. Niciu MJ, Ionescu DF, Mathews DC, Richards EM, Zarate CA (2013): Second messenger/signal transduction pathways in major mood disorders: Moving from membrane to mechanism of action, part I: Major depressive disorder. CNS Spectr 18:231-241.
27. Duric V, Banasr M, Licznerski P, Schmidt HD, Stockmeier CA, Simen AA, et al. (2010): A negative regulator of MAP kinase causes depressive behavior. Nat Med 16:1328-1332.
28. Di Benedetto B, Radecke J, Schmidt MV, Rupprecht R (2013): Acute antidepressant treatment differently modulates ERK/MAPK activation in neurons and astrocytes of the adult mouse prefrontal cortex. Neuroscience 232:161-168.
29. Akbarian S, Davis RJ (2010): Keep the 'phospho' on MAPK, be happy. Nat Med 16:1187-1188.
30. Yaniv SP, Lucki A, Klein E, Ben-Shachar D (2010): Dexamethasone enhances the norepinephrine-induced ERK/MAPK intracellular pathway possibly via dysregulation of the alpha2-adrenergic receptor: implications for antidepressant drug mechanism of action. Eur J Cell Biol 89:712-722.